Zoetis Announces USDA Licensure of VANGUARD®crLyme Vaccine for Dogs

First and only canine Lyme disease vaccine that can help address outer surface protein C variability

FLORHAM PARK, N.J. – January 6, 2016 – Zoetis Inc. today announced that the U.S. Department of Agriculture (USDA) has licensed VANGUARD®crLyme vaccine to aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi, the causative agent of Lyme disease in dogs. This next-generation vaccine has been developed to drive an immune response against two of the bacterium’s most relevant proteins – outer surface protein A (OspA) and outer surface protein C (OspC).

VANGUARD® crLyme is a multivalent vaccine which contains an OspA protein and a single OspC protein that is composed of antigenic material from seven common types of OspC found in Lyme-infected dogs in the U.S.1 Its uniquely targeted design helps provide a broad spectrum of coverage while delivering a low-reactive vaccine by minimizing the amount of extraneous proteins administered to the dog.

The new vaccine has been demonstrated to be safe and efficacious in laboratory and field studies. VANGUARD® crLyme will be administered in two doses, three weeks apart, to healthy dogs eight weeks of age or older. Annual re-vaccination is recommended for maximum protection.

“Lyme is a serious and common disease that you want to help prevent, rather than treat,” said Shelley L. Stanford, DVM, MS, MBA, Group Director, Companion Animal Division Veterinary Professional Services at Zoetis. “We are pleased to be able to offer veterinarians the first and only vaccine that considers the variability of OspC in a selectively designed formulation that also minimizes extraneous proteins.”

Scientific research has demonstrated that there are multiple variants of OspC that have been associated with Lyme-infected dogs.1 Stimulating the immune system to develop a relevant OspC response has been challenging because until today, it was not immunologically feasible to develop a vaccine that includes whole-length OspC proteins.2 Existing commercially available vaccines contain at most only one type of OspC.

“Lyme disease presents a growing threat to dogs across the U.S.,” said Richard E. Goldstein, DVM, DACVIM, DECVIM-CA, Chief Medical Officer at the Animal Medical Center in New York City. “As people travel with their pets more often, cases of Lyme disease are being diagnosed well outside of the Northeast, where Lyme has historically been most prevalent. As an essential aspect of complete Lyme prevention, vaccinations help assure owners that their dogs are protected at home or away. We welcome this new and unique vaccine to help pets avoid the debilitating effects of Lyme disease.”

According to the Companion Animal Parasite Council™, one out of 16 dogs tested will receive a positive diagnosis of Lyme disease.3  The Baker Institute for Animal Health at Cornell University reports that Lyme disease is now one of the most common vector-borne diseases seen in dogs in the U.S.4

For more information about this new vaccine, please visit www.VanguardcrLyme.com or call Zoetis Customer Service at 1-888-Zoetis1 (1-888-963-8471).

About Zoetis

Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenues of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetisUS.com.

For Further Information,Contact:

Colleen White

Brad Carmony
Archer Malmo

1 Rhodes DV, Earnhart CG, Mather TN, Meeus PF, Marconi RT. Identification of Borrelia burgdorferi OspC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design. Vet J. 2013;198(2):412-418.
2 Dr. Richard Marconi personal communication.
3 Companion Animal Parasite Council. CAPC Parasite Prevalence Maps 2015. http://www.capcvet.org/parasite-prevalence-maps/. Accessed August 24, 2015.
4 Cornell University School of Veterinary Medicine Baker Institute of Animal Health, “An Overview of Lyme Disease in Dogs.” http://bakerinstitute.vet.cornell.edu/animalhealth/page.php?id=1101 Accessed August 26, 2015.



Mon–Fri, 8:30am–6:30pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.